Related Experiment Video
Updated: May 20, 2025
04:49
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
46
Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic
Dijana Perković1,2, Marin Petrić1, Maja Maleš2
1Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, Croatia.
Current Issues in Molecular Biology
|March 26, 2025
Summary
Biological disease-modifying antirheumatic drugs (bDMARDs) significantly reduced serum uric acid (SUA) levels in psoriatic arthritis (PsA) patients. Interleukin-17 (IL-17) inhibitors showed a particularly notable decrease in SUA levels.
Area of Science:
- Rheumatology
- Pharmacology
- Biochemistry
Background:
- Psoriatic arthritis (PsA) is a chronic inflammatory condition.
- Elevated serum uric acid (SUA) levels are observed in PsA patients, but the impact of treatments is not fully understood.
Purpose of the Study:
- To investigate the effect of various biological disease-modifying antirheumatic drugs (bDMARDs) on SUA levels in patients with PsA.
- To compare the efficacy of different bDMARD classes, specifically IL-17 inhibitors and TNFα inhibitors, in modulating SUA levels.
Main Methods:
- Retrospective analysis of 87 PsA patients treated with bDMARDs from January 2007 to June 2021.
- Inclusion of patients treated with IL-17 inhibitors (secukinumab, ixekizumab) and TNFα inhibitors (golimumab, infliximab, adalimumab, certolizumab pegol, etanercept).
Main Results:
- A significant decrease in SUA levels was observed in 69% of patients after 3-6 months.
- The average SUA decrease was 9.4 µmol/L (p=0.039), with a more pronounced reduction in patients treated with IL-17 inhibitors (12.6 µmol/L, p=0.013) compared to TNFα inhibitors (7.3 µmol/L, p=0.386).
- Specific drugs like golimumab, infliximab, secukinumab, and etanercept demonstrated notable SUA level reductions.
Conclusions:
- bDMARDs are effective in managing PsA disease activity.
- A significant reduction in SUA levels was observed, particularly with IL-17 inhibitors.
- Further research is warranted to identify the most potent bDMARD for lowering SUA levels in PsA.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
119
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
119
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106
01:16Antihypertensive Drugs: Action of Diuretics
596
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
596
01:29Drugs for Treatment of Ulcerative Colitis in IBD
114
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
114
01:29Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
320
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
320